Table 4: hSBA-MenC, hSBA-MenY antibody responses after Hib-MenCY-TT vaccination.

ReferenceVaccine dose 1–3Vaccine dose 4Timepoint 𝑁 hSBA ≥ 1 : 4hSBA 1 : 8GMT
%[95% CI]%[95% CI]Value[95% CI]

hSBA-MenC

Marchant et al., 2010 [82] & Marshall et al., 2010 [83] 2, 4, 6 + 12–15 months of ageHib-MenCY-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + 7vCRMPD312197.5[92.9–99.5]95.9[90.6–98.6]523.0[398.8–686.0]
Pre-D46390.5[80.4–96.4]90.5[80.4–96.4]71.8[48.0–107.5]
PD46596.9[89.3–99.6]96.9[89.3–99.6]657.1[438.4–984.8]
PD4 (Y1)11696.6[91.4–99.1]96.6[91.4–99.1]150.1[116.5–193.4]
Hib-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + 7vCRMPD43594.3[80.8–99.3]94.3[80.8–99.3]72.5[46.4–113.3]
PD4 (Y1)4870.8[55.9–83.0]70.8[55.9–83.0]26.3[14.8–46.5]

Nolan et al., 2011 [84] 2, 4, 6 + 12–15 months of ageHib-MenCY-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + MMR + VARPD383100[95.7–100]100[95.7–100]379[295–489]
Pre-D413493.3[87.6–96.9]93.3[87.6–96.9]97.7[74.0–129]
PD413299.2[95.9–100]99.2[95.9–100]1808[1398–2337]
MenC-CRM197 + Hib-TT + 7vCRM
DTPa-HBV-IPV
Hib-MenCY-TT + MMR + VARPD328100[87.7–100]100[87.7–100]254[193–335]
Pre-D45485.2[72.9–93.4]85.2[72.9–93.4]34.6[22.8–52.6]
PD44395.3[84.2–99.4]95.3[84.2–99.4]172[94.7–311]

Bryant et al., 2011 [85] 2, 4, 6 + 12–15 months of ageHib-MenCY-TT + DTPa-HBV-IPV + 7vCRM (Mexico) Hib-MenCY-TT + MMR + VARPD313499.3[95.9–100]99.3[95.9–100]3172.6[2657.9–3786.8]
PD439100[91.0–100]100[91.0–100]10132.9[8008.0–12821.7]
Hib-MenCY-TT + DTPa-HBV-IPV + 7vCRM (US)Hib-MenCY-TT + MMR + VARPD349198.8[97.4–99.6]98.8[97.4–99.6]967.6[864.0–1083.5]
Pre-D442096.0[93.6–97.6]96.0[93.6–97.6]176.5[153.9–202.4]
PD433198.5[96.5– 99.5]98.5[96.5– 99.5]2039.8[1746.3–2382.6]

hSBA-MenY

Marchant et al., 2010 [82] & Marshall et al., 2010 [83] 2, 4, 6 + 12–15 months of ageHib-MenCY-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + 7vCRMPD314191.5[85.6–95.5]89.4[83.1–93.9]139.8[102.6–190.5]
Pre-D46654.5[41.8–66.9]50.0[37.4–62.6]12.2[7.7–19.1]
PD46595.4[87.1–99.0]95.4[87.1–99.0]246.6[168.0–362.1]
PD4 (Y1)10584.8[76.4–91.0]83.8[75.3–90.3]128.8[86.2–192.5]
Hib-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + 7vCRMPD43560.0[42.1–76.1]57.1[39.4–73.7]11.1[6.5–19.0]
PD4 (Y1)4766.0[50.7–79.1]66.0[50.7–79.1]41.1[20.4–82.9]

Nolan et al., 2011 [84] 2, 4, 6 + 12–15 months of ageHib-MenCY-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + MMR + VARPD385100[95.8–100]100[95.8–100]86.4[68.9–108.3]
Pre-D411491.2[84.5–95.7]90.4[83.4–95.1]81.2[58.6–112.6]
PD412297.5[93.0–99.5]97.5[93.0–99.5]1002[741–1356]

Bryant et al., 2011 [85] 2, 4, 6 + 12–15 months of ageHib-MenCY-TT + DTPa-HBV-IPV + 7vCRM (Mexico)Hib-MenCY-TT + MMR + VARPD313599.3[95.9–100]99.3[95.9–100]837.2[696.4–1006.3]
PD440100[91.2–100]100[91.2–100]5775.8[4488.9–7431.7]
Hib-MenCY-TT + DTPa-HBV-IPV + 7vCRM (US)Hib-MenCY-TT + MMR + VARPD348196.3[94.2–97.8]95.8[93.7–97.4]236.6[205.7–272.1]
Pre-D441993.6[90.8–95.7]92.8[89.9–95.1]117.5[101.3–136.2]
PD434298.8[97.0–99.7]98.8[97.0–99.7]1389.5[1205.0–1602.2]

𝑁 : numbers of subjects with available data, 95% CI: 95% confidence interval, GMT: Geometric Mean Titre, %: percentage of subjects with titre within the specified range, PD3: one month after dose 3 (ATP Cohort for Immunogenicity), Pre-D4: just prior dose 4 (ATP Cohort for Persistence), PD4: one month after dose 4 (ATP Cohort for Immunogenicity), PD4 (Y1): one year after dose 4 (ATP cohort for Persistence Year 1), Results of this table were previously published [8285].